GoodRx has launched two major initiatives to make GLP-1 medications more affordable and accessible: a telemedicine subscription program called GoodRx for Weight Loss and a new introductory cash price of $199 per month for Ozempic and Wegovy injection pens through a partnership with Novo Nordisk.
The GoodRx for Weight Loss subscription offers an end-to-end telemedicine experience for patients pursuing GLP-1 treatment, covering everything from virtual consultations and prescriptions to ongoing clinical support. It ensures patients are prescribed only FDA-approved medications, avoiding compounded alternatives. Subscribers benefit from transparent pricing, flexible fulfillment options—such as in-store pickup or home delivery—and continued medical guidance to monitor progress and adjust treatment as needed. The service is available for an introductory rate of $39 per month through January 2026, after which it will cost $119 per month.
In partnership with Novo Nordisk, GoodRx is also offering a limited-time introductory price of $199 per month for the lowest doses of Ozempic and Wegovy to first-time, self-paying customers. After two months, pricing transitions to $349 per month. The offer is available nationwide and is intended to make these highly sought-after GLP-1 therapies more affordable for patients seeking safe, science-backed treatments.
GoodRx President and CEO Wendy Barnes emphasized that the company’s goal is to create a “consumer-first model for affordable GLP-1 treatment” that combines trusted medication access, transparent pricing, and nationwide pharmacy integration to raise the standard for affordability and trust in weight-loss care.
Click here to read the original news story.